Last reviewed · How we verify
VYKAT XR
VYKAT XR is a sustained-release formulation of potassium that provides controlled delivery of potassium to treat hypokalemia.
VYKAT XR is a sustained-release formulation of potassium that provides controlled delivery of potassium to treat hypokalemia. Used for Hypokalemia (low serum potassium).
At a glance
| Generic name | VYKAT XR |
|---|---|
| Sponsor | Soleno Therapeutics, Inc. |
| Drug class | Potassium supplement |
| Target | Potassium ion (K+) |
| Modality | Small molecule |
| Therapeutic area | Electrolyte replacement / Internal Medicine |
| Phase | FDA-approved |
Mechanism of action
VYKAT XR uses Soleno's proprietary AQORAL technology to deliver potassium in a controlled, extended-release manner throughout the gastrointestinal tract. This approach aims to minimize gastrointestinal irritation and tolerability issues associated with conventional potassium supplements while maintaining therapeutic efficacy in correcting low serum potassium levels.
Approved indications
- Hypokalemia (low serum potassium)
Common side effects
- Gastrointestinal upset
- Nausea
- Abdominal discomfort
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VYKAT XR CI brief — competitive landscape report
- VYKAT XR updates RSS · CI watch RSS
- Soleno Therapeutics, Inc. portfolio CI